Envue Medical, Inc. (FEED) — SEC Filings
Envue Medical, Inc. (FEED) — 50 SEC filings. Latest: 8-K (Dec 30, 2025). Includes 32 8-K, 6 10-Q, 4 DEF 14A.
View Envue Medical, Inc. on SEC EDGAR
Overview
Envue Medical, Inc. (FEED) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: ENvue Medical, Inc. announced on December 17, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific deta
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Envue Medical, Inc. is neutral.
Filing Type Overview
Envue Medical, Inc. (FEED) has filed 32 8-K, 6 10-Q, 4 DEF 14A, 1 DEFA14A, 4 S-1/A, 1 10-K, 1 SC 13G/A, 1 10-K/A with the SEC between Apr 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of FEED's 47 recent filings, 4 were flagged as high-risk, 27 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2.241 million |
| Net Income | $510 thousand |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $6.950 million |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Doron Besser, M.D.
- Zeev Rotstein, M.D.
- David Johnson
- Nino Pionati
- Alison Geiger Burgett
- Dr. David L. Smith
- Mr. Robert J. Smith
- Mr. Jonathan S. Lerman
- Brian Murphy
- Rick A. Werner, Esq.
- Alla Digilova, Esq.
- Mr. David L. Smith
- Mr. Brian Murphy
- David L. Johnson
Industry Context
NanoVibronix operates in the medical device sector, specifically focusing on therapeutic devices. This industry is characterized by high R&D investment, stringent regulatory pathways (FDA approval), and a competitive landscape with both established players and innovative startups. Trends include increasing adoption of non-invasive therapies and digital health integration.
Top Tags
corporate-governance (7) · filing (5) · 10-Q (5) · financials (5) · sec-filing (5) · management-change (4) · board-of-directors (4) · material-agreement (4) · registration (4) · disclosure (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income (loss) for Q3 2025 (in thousands) | $510 | Improved from $(998) thousand in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 (in thousands) | $(5,333) | Increased from $(2,274) thousand in the prior year period |
| Revenue for Q3 2025 (in thousands) | $722 | Increased from $376 thousand in Q3 2024 |
| Revenue for nine months ended Sept 30, 2025 (in thousands) | $2,241 | Increased from $2,114 thousand in the prior year period |
| Cash and cash equivalents as of Sept 30, 2025 (in thousands) | $6,950 | Increased from $752 thousand at Dec 31, 2024 |
| Accumulated deficit as of Sept 30, 2025 (in thousands) | $76,858 | Indicates significant historical losses |
| Net cash used in operating activities for nine months ended Sept 30, 2025 (in thousands) | $(6,696) | Highlights ongoing negative operational cash flow |
| Net cash provided by financing activities for nine months ended Sept 30, 2025 (in thousands) | $12,820 | Primary source of cash increase |
| March 2025 Reverse Stock Split ratio | 1-for-11 | Adjusted common stock shares |
| August 2025 Reverse Stock Split ratio | 1-for-10 | Adjusted common stock shares |
| Annual Meeting Date | December 4, 2025 | Date stockholders will vote on proposals |
| Record Date | October 27, 2025 | Date for determining eligible voters |
| Common Stock Shares Outstanding | 1,011,102 | Number of voting shares on Record Date |
| Potential Dilution Threshold | 19.99% | Issuance of common stock underlying convertible preferred stock and warrants may exceed this percentage of outstanding common stock |
| Director Nominees | 5 | Number of individuals proposed for election to the Board |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Envue Medical, Inc. (FEED)?
Envue Medical, Inc. has 50 recent SEC filings from Apr 2024 to Dec 2025, including 32 8-K, 6 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of FEED filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Envue Medical, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Envue Medical, Inc. (FEED) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Envue Medical, Inc.?
Key financial highlights from Envue Medical, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for FEED?
The investment thesis for FEED includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Envue Medical, Inc.?
Key executives identified across Envue Medical, Inc.'s filings include Doron Besser, M.D., Zeev Rotstein, M.D., David Johnson, Nino Pionati, Alison Geiger Burgett and 9 others.
What are the main risk factors for Envue Medical, Inc. stock?
Of FEED's 47 assessed filings, 4 were flagged high-risk, 27 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Envue Medical, Inc.?
Forward guidance and predictions for Envue Medical, Inc. are extracted from SEC filings as they are enriched.